Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777927 | 0.87 | P2RX7 (0.38) | P2RX7PPARGPPARA | |
| SCHEMBL21830210 | 0.82 | MAPT (0.44) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL28564086 | 0.77 | RORC (0.39) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL21777896 | 0.77 | MAPT (0.46) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL26981969 | 0.77 | MAPT (0.45) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL29588708 | 0.77 | TEAD1 (0.47) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL28564050 | 0.76 | SMN1; SMN2 (0.49) | MAPTSMN1; SMN2HTTNPSR1MEN1 | |
| SCHEMBL25591485 | 0.73 | USP2 (0.44) | SMN1; SMN2 | |
| SCHEMBL21788887 | 0.72 | MAPT (0.47) | MAPTRORCSMN1; SMN2HTTNPSR1 | |
| SCHEMBL29789103 | 0.72 | MAPT (0.47) | MAPTRORCSMN1; SMN2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112867539-A | Cardiac muscle segment inhibitor | 赛特凯恩蒂克公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.